On November 9, before the "2019 China-Japan Advanced Medical and New Drug R&D Summit Forum & Achievements Transformation Conference", a delegation coming all the way from Japan paid a visit to the State Key Laboratory of Biotherapy of Sichuan University under the guidance of Sichuan International Medical Exchange & Promotion Association. In the afternoon, the delegation firstly visited Sichuan University, and then took seats in the lecture hall on the first floor of the School of Pharmacy.

The dual-appointed Professor Mi Peng, professor of National Key Laboratory of Biotherapy of Sichuan University, and doctoral tutor from the Radiology Department of West China Hospital, introduced in detail the research orientation and major research projects of the State Key Laboratory of Biotherapy as well as its talents introduction policy, team building, new drug R&D progress, thesis achievements, achievements transformation and the use and management of equipment. The main research fields and orientation of the State Key Laboratory of Biotherapy include several major basic theories of biotherapy for human disease and development of biotechnological drugs and alike. It has formed six multidisciplinary, interdisciplinary and integral technical platforms and research fields with theoretical base on molecular biology, oncology, immunology, genomics, protein science, and chemical biology.  In the past five years, the laboratory has jointly undertaken more than 60 national major programs such as the "973" special project (where the chief scientist works) of the national key fundamental research and development plan and its sub-projects, the"863" key or major special projects of the national high-tech research and development plan, preliminary research for major projects of fundamental research by Ministry of Science and Technology, programs from Science Fund for Innovative Research Groups and Young Scientists Fund, key programs of the National Natural Science Fund of China, etc., and more than 100 national natural science foundation projects and provincial and ministerial-level scientific research projects.

Professor Mi Peng mentioned that the "2019 China-Japan Advanced Medical and New Drug R&D Summit Forum & Achievements Transformation Conference" will be held tomorrow, which will bring many advanced medical technologies and biomedical products worthy of investment for transformation and industrialization, believing it can greatly promote for the exchange and cooperation between the two countries in biomedicine with common development. One of the highlights of the conference, say the "Through Train of China-Japan Biomedical Achievements Transformation" , will be the best way to explore the rapid settlement and capitalization of biomedical achievements, not only by significantly reducing the  time of transformation and maximizing the efficiency of industrialization for the biomedical achievements, but also by largely shortening the straight-line distance between the settlement of the Japanese advanced pharmaceutical projects in China and the settlement of Chinese first-class medical technology and new drug achievements transformation, which can truly increase the interactivity and timeliness of the transformation and docking of the scientific and technological achievements and help the marketing of excellent scientific and technological project achievements.

Professor Tokushima Yamato from Graduate School of Tokushima University gave a wonderful report on some achievements in stem cell therapy applied for paralysis of the lower limbs by animal models, and Professor Takahata Yokiya of Tokyo Medical University gave a vivid presentation on the value and role of Exosome-based in diagnosis and treatment.

Later, Professor Mi Peng led the delegation to visit the laboratory in personal, and introduced the laboratory’s basic profile, development history, current standing in medical treatment worldwide and the latest research orientations. He also introduced the design of the targeted identification drug, the construction and operation experience of the screening experiment building. He mentioned that the State Key Laboratory of Biotherapy had made great achievements at such a staggering rate under the leadership of Academician Wei, especially its trail blazing in the transformation of the biomedical achievements.

Through this pre-conference visit, and with introduction to guests from Japan regarding the State Key Laboratory of Biotherapy at Sichuan University, the Japanese guests obtained a deeper perception and awareness of medical and pharmaceutical development in China. It really provided good opportunities to enhance China-Japan medical academic exchanges and promote the medical achievements transformation.